Kimberly Podsada, BSN, RN, MSN, NP-C, CNS, is a nurse practitioner at University of California San Diego Health.
CDK4/6 Inhibition Customizes Frontline HR+, HER2- mBC Treatment
According to Kimberly Podsada, BSN, RN, MSN, NP-C, CNS, the availability of 3 CDK4/6 inhibitors in first-line mBC therapy gives patients more choices.
How CDK4/6 Inhibitors Enable More Personalized Treatment in HR+ mBC
The amount of CDK4/6-targeting treatment options available for patients with HR-positive breast cancer allows providers to personalize treatment.
Relacorilant Combo Sustains Ovarian Cancer Benefit Post Platinum Break
Genomic Changes May Drive Sotorasib KRAS G12C+ Combo Resistance in CRC
Relacorilant/Nab-Paclitaxel Is Convenient, Safe in Ovarian Cancer
Neoadjuvant Nivolumab Regimen Improves OS in Resectable NSCLC